MDMA-assisted massed prolonged exposure for PTSD
Post-Traumatic Stress Disorder
Enrolment: 20 · Results not recorded
Loading the evidence…
Drug · Monoamine releasing agent at the serotonin (SLC6A4), dopamine (SLC6A3) and noradrenaline (SLC6A2) transporters; mechanism annotated for PTSD indication
4 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Post-Traumatic Stress Disorder
Enrolment: 20 · Results not recorded
Post Traumatic Stress Disorder · Moral Injury
Enrolment: 60 · Results not recorded
Post Traumatic Stress Disorder
Enrolment: 40 · Results not recorded
Post Traumatic Stress Disorder
Enrolment not recorded · Results not recorded
Healthy
Enrolment: 24 · Results not recorded
Stimulant Use · Social Behavior
Enrolment: 43 · Results not recorded
Bulimia Nervosa
Enrolment: 40 · Results not recorded
Startle Response
Enrolment: 34 · Results not recorded
Autism Spectrum Disorder
Enrolment: 40 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Closed head minimal traumatic brain injury
A single MDMA dose before minimal TBI minimised visual and spatial memory impairment and reversed the injury-induced tyrosine hydroxylase decrease.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.